2024.11,Bosutinib,Bosulif,Markets and News,API,Bosutinib Monohydrate,918639-08-4

Abstract:
Bosutinib, marketed under the brand name Bosulif, is a tyrosine kinase inhibitor approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Initially developed by Wyeth and later acquired by Pfizer, Bosutinib was approved by the U.S. FDA in 2012 and by the European Medicines Agency (EMA) in 2013. As an ATP-competitive inhibitor of BCR-ABL and Src family kinases, Bosutinib has demonstrated efficacy in patients who are resistant or intolerant to other therapies like imatinib, dasatinib, and nilotinib. This paper explores Bosutinib's development, market performance, the competitive landscape, and the implications of generic drugs entering the CML market. The paper also examines recent approvals and its expanded use in pediatric populations, along with Pfizer's strategies to maintain market share.

Keywords:
Bosutinib, Bosulif, chronic myelogenous leukemia, CML, Wyeth, Pfizer, generic drugs, market competition, BCR-ABL, tyrosine kinase inhibitors, pediatric treatment,Bosutinib Monohydrate,918639-08-4.

Introduction:
Bosutinib (trade name Bosulif) is an oral, small-molecule tyrosine kinase inhibitor used in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), a form of leukemia characterized by the presence of the Philadelphia chromosome translocation between chromosomes 9 and 22. The drug is particularly used in cases of CML that are resistant to or intolerant of first-line therapies like imatinib (Gleevec), nilotinib (Tasigna), and dasatinib (Sprycel).

Originally synthesized by Wyeth Pharmaceuticals and later acquired by Pfizer, Bosutinib was approved by the U.S. Food and Drug Administration (FDA) in September 2012 and by the European Medicines Agency (EMA) in March 2013. Its dual action as a BCR-ABL and Src kinase inhibitor differentiates it from other tyrosine kinase inhibitors, giving it a unique role in treating resistant CML. This paper aims to provide an overview of Bosutinib’s development, its market performance, the competitive environment, and the role of generics and new formulations in shaping the future of CML therapy.

1. Development and Approval
Bosutinib was developed as part of the search for new treatments for Philadelphia chromosome-positive CML, a condition that arises due to the abnormal fusion of the BCR and ABL genes, leading to the production of the BCR-ABL fusion protein, a driver of uncontrolled cell proliferation. Bosutinib is an ATP-competitive tyrosine kinase inhibitor that targets the BCR-ABL kinase, thereby inhibiting cancer cell proliferation. In addition to BCR-ABL, Bosutinib also inhibits other kinases, such as Src, Lyn, and Hck, which contribute to the progression of CML and other cancers.

Bosutinib’s ability to inhibit imatinib-resistant forms of BCR-ABL made it an attractive option for patients who have not responded to first-line therapies. After successful clinical trials, Bosutinib was granted FDA approval in 2012 and EMA approval in 2013 for the treatment of adult patients with Ph+ CML, particularly those who showed resistance or intolerance to previous therapies. The approval was based on Phase III clinical trials, which demonstrated that Bosutinib was effective in reducing the number of leukemic cells in patients previously treated with other kinase inhibitors.

In recent years, the FDA expanded the use of Bosutinib to include pediatric patients, making it available for children aged one year and older with CML who have either newly diagnosed disease or resistance to other treatments. This expanded approval enhances Bosutinib's market potential, as pediatric CML treatments are relatively limited compared to adult therapies.

2. Pharmacological Profile and Clinical Use
Bosutinib works by inhibiting BCR-ABL and Src family kinases, which are involved in the progression of CML. In preclinical studies, Bosutinib demonstrated activity against 16 out of 18 imatinib-resistant forms of BCR-ABL. However, it has limited effectiveness against certain mutations, such as the T315I and V299L mutations, which confer resistance to many kinase inhibitors.

The clinical use of Bosutinib is primarily for adult patients with chronic phase, accelerated phase, and blast phase Ph+ CML who have not responded well to other therapies. Bosutinib’s side effects include gastrointestinal disturbances, liver toxicity, and bone marrow suppression. However, the overall efficacy of Bosutinib in controlling CML, especially in patients with resistant mutations, has led to its acceptance as a second-line or third-line therapy.

The drug is metabolized by the CYP3A4 enzyme, which means that its bioavailability can be influenced by other drugs that affect this enzyme, such as antifungals or antibiotics. This interaction needs to be carefully managed during treatment.

3. Market Performance and Competition
In its peak year, Bosulif generated $575 million in global sales as reported by Pfizer’s FY2022 financial report. Although Bosutinib is a key treatment for Ph+ CML, its market share is affected by the presence of other highly effective tyrosine kinase inhibitors, particularly nilotinib (Tasigna), dasatinib (Sprycel), and imatinib (Gleevec). These competitors dominate the market, with Nilotinib generating $1.9 billion in sales in 2022 and Dasatinib generating $2.165 billion in the same year.

Despite this competition, Bosutinib’s unique profile—particularly its ability to inhibit Src family kinases—has enabled it to carve out a niche, particularly in patients who are resistant to other therapies. However, the availability of generics for older drugs like imatinib has added competitive pressure on Bosutinib’s market share.

4. Generic Drugs and Market Dynamics
As with many patented pharmaceutical products, Bosutinib is facing competition from generic versions of other tyrosine kinase inhibitors, including imatinib, which has been available as a generic for several years. The entry of generic imatinib has driven prices down in many markets, increasing the affordability of first-line treatments but also eroding the potential market for newer drugs like Bosutinib. However, Bosutinib’s patent is expected to expire in the near future, allowing generic alternatives to enter the market, further intensifying the competition.

Generic versions of Bosutinib will likely lead to a reduction in drug prices, improving accessibility, particularly in developing markets. However, the shift to generics could lead to reduced revenues for Pfizer, particularly if Bosutinib's efficacy is not significantly superior to other drugs in its class.

5. Recent Developments and Future Outlook
In response to the evolving market dynamics, Pfizer has sought to expand Bosutinib’s indications, including the approval of a new capsule dosage form of Bosulif (50mg and 100mg strengths), which enhances treatment accessibility and convenience for patients. Additionally, the BCHILD clinical trial, which evaluated Bosutinib in pediatric patients, demonstrated promising results, with a significant proportion of children showing reductions in abnormal leukemia cells. This expands the market potential for Bosutinib, particularly in younger patients with limited treatment options.

Looking forward, the competition in the CML market is expected to intensify, with generics and biosimilars potentially taking over a larger share of the market. Bosutinib will continue to face challenges from other tyrosine kinase inhibitors and the entry of generics, but its unique profile may allow it to maintain a role in treating patients with specific resistance profiles.

6.Active Pharmaceutical Ingredient
918639-08-4
Bosutinib Monohydrate, (chemical grade, purity ≥99.0%) are currently supplied by our company. [Own compliance factory, fully support factory audit] For details, you can call the bottom line to get the latest price of the product!
 
Disclaimer:Products are only available to countries where there is no valid patent protection. Products still covered by patents rights are available exclusively for experimental or registration purpose pursuant to national applicable law, and shall be sold in strict accordance with the laws of the People's Republic of China and the laws of the Buyer's country. All products are not for human use. Buyer is obligated for evaluation of the patent situation in its domestic market and shall be held liable for uses which do not fall within the scope of the experimental or registration use exception and are not permitted by national applicable law.

Conclusion:
Bosutinib (Bosulif) represents an important treatment option for chronic myelogenous leukemia (CML), particularly for patients resistant to or intolerant of first-line therapies. Developed by Wyeth and later acquired by Pfizer, Bosutinib’s market performance has been solid, though it faces stiff competition from other tyrosine kinase inhibitors and the growing presence of generics. The expanded pediatric indication and new dosage forms may help bolster its market position, but the future of Bosutinib in the CML treatment landscape will largely depend on the competitive dynamics and the continued development of generic drugs and biosimilars.

References:
Bosutinib Approval for CML. (2012). U.S. Food and Drug Administration (FDA).
Pfizer Annual Report 2022. Pfizer Inc.
BCHILD Trial for Bosutinib in Pediatric CML. (2022). ClinicalTrials.gov.
European Medicines Agency Approval of Bosutinib. (2013). European Medicines Agency.
CML Market Dynamics and Competition. (2023). IMS Health.
Generic Drugs in the CML Treatment Market. (2023). Journal of Oncology Pharmacy Practice.

Photo credit: | Pexels (pictures are not products, not actual characters, for display only)
If there is infringement, apologize for deletion, if there is mistake, welcome criticism and correction
In any event, the information or opinions expressed herein are for informational purposes only and do not constitute investment advice to anyone